Descarga

More documents

Recommendations

Info

ATLL AND CHEMOTHERAPY 5 1 2 3 1 1 1 7 CHOP CNOP INF-AZT CVP MTX ALL REGIMEN Complete response Parcial response Progression disease B. Beltran et al .Adult T cell Leukemia/Lymphoma (ATLL) in Peru. Poster Next questions Ford Lauderlau 2004
Istituto “Seràgnoli” - Bologna
Page 1 and 2: NUEVOS AVANCES EN EL DIAGNOSTICO Y
Page 3 and 4: GENERALIDADES 8/100000 casos nuevo
Page 5 and 6: PATOGENIA Recientemente más virus
Page 7 and 8: EPIDEMIOLOGIA • Linfomas con dist
Page 9 and 10: Distribution andPathology Character
Page 11 and 12: Incidencia de Linfomas en el Hospit
Page 13 and 14: CARACTERISTICAS CLINICAS Istituto
Page 15 and 16: LINFOMAS NO HODGKIN: EDAD MEDIA 62.
Page 17 and 18: LINFOMAS NO HODGKIN Grado de Linfom
Page 19 and 20: Estirpe B Estirpe T Total FENOTIPO
Page 21 and 22: Porcentaje SOBREVIDA POR GRADO HIST
Page 23 and 24: Porcentaje 1.2 1.0 .8 .6 .4 .2 0.0
Page 25 and 26: Porcentaje 1.2 1.0 .8 .6 .4 .2 0.0
Page 27 and 28: Istituto “Seràgnoli” - Bologna
Page 39 and 40: LINFOMAS CUTÁNEOS • Entidad que
Page 43 and 44: LINFOMA/LEUCEMIA T DEL ADULTO Istit
Page 45 and 46: CLINICAL PRESENTATION Acute Lymph
Page 47: Istituto “Seràgnoli” - Bologna
Page 51 and 52: ANTICUERPOS MONOCLONALES Y LINFOMAS
Page 57 and 58: ALEMTUZUMAB IN PATIENTS WITH ADVANC
Page 59 and 60: EXPERIENCIA PERUANO VENEZOLANO Belt
Page 61 and 62: Tratamiento del Linfoma Cutáneo de
Page 63 and 64: Ag e Se x Histol ogy CARACTERISTICA
Page 65 and 66: NUEVOS AGENTES TERAPEUTICOS
Page 70 and 71: BENDAMUSTINE
Page 73: BRENTUXIMAB Aprobado en entidades

Descarga

Create successful ePaper yourself

Delete template?

Save as template?